Bisphosphonates in bone diseases other than osteoporosis

Joint Bone Spine

Volumn 69, Issue 1, 2002, Pages 19-27

  Orcel, Philippe ^a   Beaudreuil, Johann ^a  

^a CENTRE VIGGO PETERSEN   (France)

Author keywords

Bisphosphonates; Bone resorption; Fibrous dysplasia; Malignant osteolysis; Osteogenesis imperfecta; Paget's disease

Indexed keywords

ALENDRONIC ACID; BANDRONAT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; LYTOS; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BACKACHE; BONE DISEASE; CHRONIC ARTHRITIS; COMPLEX REGIONAL PAIN SYNDROME; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FIBROUS DYSPLASIA; GASTROINTESTINAL SYMPTOM; HUMAN; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; REVIEW; SPINE INJURY; STANDARD; TREATMENT INDICATION;

EID: 0036163574     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(01)00336-0     Document Type: Review

References (68)

1. Mechanisms of action of bisphosphonates
2. Bisphosphonates et traitement de l'ostéoporose
3. Ostéoporose cortisonique
4. Alendronate for the treatment of osteoporosis in men
5. Treatment of bone diseases with bisphosphonates, excluding osteoporosis
6. L'hyperrésorption osseuse au cours du myélome multiple
7. Bisphosphonates en cancérologie
8. Hypercalcémies des affections malignes
9. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
10. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases
11. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy
12. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy
13. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
14. Bisphosphonates in the treatment of malignant bone disease
15. Effect of daily etidronate on the osteolysis of multiple myeloma
16. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
17. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: A multicenter study
18. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
19. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial
20. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
21. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
22. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
23. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
24. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial
25. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
26. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
27. Adjuvant Clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial
28. Pamidronate prevents skeletal complications and its effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long-term follow-up of two randomized, placebo-controlled trials
29. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
30. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
31. Les moyens thérapeutiques: Les médicaments et leurs mécanismes d'action
32. The management of Paget's disease of bone
33. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone
34. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone
35. Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study
36. Paget's disease: Acquired resistance to one aminobisphosphonate with retained response to another
37. Pamidronate in the treatment of Paget's disease
38. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone
39. Long-term aminobisphosphonate treatment of fibrous dysplasia: Spectacular increase in bone density
40. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
41. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis
42. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age
43. Treatment of severe, recalcitrant reflex sympathetic dystrophy: Assessment of efficacy and safety of the second generation bisphosphonate pamidronate
44. Pooled results from 2 trials evaluating biphosphonates in reflex sympathetic dystrophy
45. Delmas PD Bisphosphonate et algodystrophie réflexe
46. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome
47. Traitement d'une fracture vertébrale ostéoporotique récente
48. Analgesic of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures
49. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients
50. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat
51. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis
52. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: A double blind placebo controlled study
53. Increased bone mass with pamidronate treatment in rheumatoid arthritis
54. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis
55. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy
56. Healing of Charcot's joint by pamidronate infusion
57. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis
58. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis
59. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement
60. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease
61. Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate)
62. Effects of intravenous etidronate and oral corticosteroids in fibrodysplasia ossificans progressiva
63. Diphosphonates for periarticular ossification
64. Osteogenesis imperfecta: Lifelong management is imperative and feasible
65. Bisphosphonate therapy in fibrous dysplasia
66. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism
67. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism
68. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism